Lates News

A recent study by Deloitte shows that the pharmaceutical industry is facing risks from the "bubble effect" due to a significant increase in demand for weight loss and diabetes drugs, leading to a substantial increase in profitability. Demand for drugs like Wegovy and Zepbound has pushed the return on investment in research and development to the highest level in years, but a report released by Deloitte on Monday points out that this actually masks the pressures faced by other areas of the industry.